{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:32:03Z","timestamp":1788546723492,"version":"build-2803163510"},"reference-count":54,"publisher":"Portland Press Ltd.","issue":"12","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,6,1]]},"abstract":"<jats:p>Phosphoinositide 3-kinase [PI3K (p110\u03b1)] is able to negatively regulate the diabetes-induced increase in NADPH oxidase in the heart. Patients affected by diabetes exhibit significant cardiovascular morbidity and mortality, at least in part due to a cardiomyopathy characterized by oxidative stress and left ventricular (LV) dysfunction. Thus, PI3K (p110\u03b1) may represent a novel approach to protect the heart from diabetes-induced cardiac oxidative stress and dysfunction. In the present study, we investigated the therapeutic potential of a delayed intervention with cardiac-targeted PI3K gene therapy, administered to mice with established diabetes-induced LV diastolic dysfunction. Diabetes was induced in 6-week-old male mice by streptozotocin (STZ). After 8 weeks of untreated diabetes, LV diastolic dysfunction was confirmed by a reduction in echocardiography-derived transmitral E\/A ratio. Diabetic and non-diabetic mice were randomly allocated to receive either recombinant adeno-associated viral vector-6 carrying a constitutively-active PI3K construct (recombinant adeno-associated-virus 6-constitutively active PI3K (p110\u03b1) (caPI3K) (rAAV6-caPI3K), single i.v. injection, 2 \u00d7 1011 vector genomes) or null vector, and were followed for a further 6 or 8 weeks. At study endpoint, diabetes-induced LV dysfunction was significantly attenuated by a single administration of rAAV6-caPI3K, administered 8 weeks after the induction of diabetes. Diabetes-induced impairments in each of LV NADPH oxidase, endoplasmic reticulum (ER) stress, apoptosis, cardiac fibrosis and cardiomyocyte hypertrophy, in addition to LV systolic dysfunction, were attenuated by delayed intervention with rAAV6-caPI3K. Hence, our demonstration that cardiac-targeted PI3K (p110\u03b1) gene therapy limits diabetes-induced up-regulation of NADPH oxidase and cardiac remodelling suggests new insights into promising approaches for the treatment of diabetic cardiomyopathy, at a clinically relevant time point (after diastolic dysfunction is manifested).<\/jats:p>","DOI":"10.1042\/cs20170063","type":"journal-article","created":{"date-parts":[[2017,5,10]],"date-time":"2017-05-10T00:10:20Z","timestamp":1494375020000},"page":"1345-1360","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Phosphoinositide 3-kinase (p110\u03b1) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction"],"prefix":"10.1042","volume":"131","author":[{"given":"Darnel","family":"Prakoso","sequence":"first","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia"},{"name":"School of Biosciences, The University of Melbourne, Parkville, Victoria 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles\u00a0J.","family":"De Blasio","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia"},{"name":"School of Biosciences, The University of Melbourne, Parkville, Victoria 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxue","family":"Qin","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia"},{"name":"Department of Pharmacology and Therapeutics, The University of Melbourne, Parkville, Victoria 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Rosli","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Kiriazis","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Qian","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Du","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia"},{"name":"Department of Medicine, Monash University, Clayton, Victoria 3800, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate\u00a0L.","family":"Weeks","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gregorevic","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia"},{"name":"Department of Physiology, The University of Melbourne, Parkville, Victoria 3010, Australia"},{"name":"Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia"},{"name":"Department of Neurology, The University of Washington, Seattle, Washington 98195, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie\u00a0R.","family":"McMullen","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia"},{"name":"Department of Medicine, Monash University, Clayton, Victoria 3800, Australia"},{"name":"Department of Physiology, Monash University, Clayton, Victoria 3800, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca\u00a0H.","family":"Ritchie","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia"},{"name":"Department of Pharmacology and Therapeutics, The University of Melbourne, Parkville, Victoria 3010, Australia"},{"name":"Department of Medicine, Monash University, Clayton, Victoria 3800, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2017,6,7]]},"reference":[{"key":"2021113011014375700_B1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diabres.2013.11.002","article-title":"Global estimates of diabetes prevalence for 2013 and projections for 2035","volume":"103","author":"Guariguata","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"2021113011014375700_B2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.hjr.0000368191.86614.5a","article-title":"The global burden of diabetes and its complications: an emerging pandemic","volume":"17","author":"van Dieren","year":"2010","journal-title":". European J. Cardiovasc. Prev. Rehab.: J. European Soc. Cardiol. Working Groups on Epidemiol. Prev. Cardiac Rehab. Exercise Physiol."},{"key":"2021113011014375700_B3","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.2337\/diacare.28.9.2130","article-title":"The burden of mortality attributable to diabetes: realistic estimates for the year 2000","volume":"28","author":"Roglic","year":"2005","journal-title":"Diabetes Care"},{"key":"2021113011014375700_B4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2337\/diacare.24.1.5","article-title":"Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy","volume":"24","author":"Poirier","year":"2001","journal-title":"Diabetes Care"},{"key":"2021113011014375700_B5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","article-title":"Role of diabetes in congestive heart failure: the Framingham study","volume":"34","author":"Kannel","year":"1974","journal-title":"Am. J. Cardiol."},{"key":"2021113011014375700_B6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.pharmthera.2014.01.003","article-title":"Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways","volume":"142","author":"Huynh","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"2021113011014375700_B7","doi-asserted-by":"crossref","first-page":"6A","DOI":"10.1016\/0735-1097(93)90455-A","article-title":"The epidemiology of heart failure: the Framingham Study","volume":"22","author":"Ho","year":"1993","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113011014375700_B8","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/j.ddmec.2010.08.001","article-title":"Diabetic cardiomyopathy: mechanisms and therapeutic targets","volume":"7","author":"Battiprolu","year":"2010","journal-title":"Drug Discover. Today: Dis. Mech."},{"key":"2021113011014375700_B9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.freeradbiomed.2013.02.021","article-title":"Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice","volume":"60","author":"Huynh","year":"2013","journal-title":"Free Rad. Biol. Med."},{"key":"2021113011014375700_B10","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1007\/s00125-012-2495-3","article-title":"Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db\/db mouse model of type 2 diabetes","volume":"55","author":"Huynh","year":"2012","journal-title":"Diabetologia"},{"key":"2021113011014375700_B11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1440-1681.2007.04585.x","article-title":"Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure","volume":"34","author":"McMullen","year":"2007","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"2021113011014375700_B12","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1073\/pnas.0606663104","article-title":"Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy","volume":"104","author":"McMullen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011014375700_B13","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/cdd.2009.150","article-title":"PI3K p110 alpha and p110 beta have differential effects on Akt activation and protection against oxidative stress-induced apoptosis in myoblasts","volume":"17","author":"Matheny","year":"2010","journal-title":"Cell Death Differ."},{"key":"2021113011014375700_B14","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1007\/s00125-012-2720-0","article-title":"Enhanced phosphoinositide 3-kinase(p110\u03b1) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes","volume":"55","author":"Ritchie","year":"2012","journal-title":"Diabetologia"},{"key":"2021113011014375700_B15","doi-asserted-by":"crossref","first-page":"H566","DOI":"10.1152\/ajpheart.00562.2008","article-title":"Phosphoinositide 3-kinase Akt signaling pathway interacts with protein kinase C beta2 in the regulation of physiologic developmental hypertrophy and heart function","volume":"296","author":"Rigor","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2021113011014375700_B16","doi-asserted-by":"crossref","first-page":"12355","DOI":"10.1073\/pnas.1934654100","article-title":"Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy","volume":"100","author":"McMullen","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011014375700_B17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.freeradbiomed.2015.04.028","article-title":"Therapeutic targeting of oxidative stress with coenzyme Q10 counteracts exaggerated diabetic cardiomyopathy in a mouse model of diabetes with diminished PI3K(p110\u03b1) signaling.","volume":"87","author":"DeBlasio","year":"2015","journal-title":"Free Radic. Biol. Med."},{"key":"2021113011014375700_B18","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1126\/science.275.5300.665","article-title":"Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate","volume":"275","author":"Franke","year":"1997","journal-title":"Science (New York, N.Y.)"},{"key":"2021113011014375700_B19","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nm1085","article-title":"Systemic delivery of genes to striated muscles using adeno-associated viral vectors","volume":"10","author":"Gregorevic","year":"2004","journal-title":"Nat. Med."},{"key":"2021113011014375700_B20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/CIRCHEARTFAILURE.112.966622","article-title":"Phosphoinositide 3-kinase p110\u03b1 is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction","volume":"5","author":"Weeks","year":"2012","journal-title":"Circ. Heart Fail."},{"key":"2021113011014375700_B21","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.2337\/db09-1456","article-title":"Cardiac-specific IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy","volume":"59","author":"Huynh","year":"2010","journal-title":"Diabetes"},{"key":"2021113011014375700_B22","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s00125-014-3171-6","article-title":"Molecular mechanisms of diabetic cardiomyopathy","volume":"57","author":"Bugger","year":"2014","journal-title":"Diabetologia"},{"key":"2021113011014375700_B23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-015-0242-z","article-title":"Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial","volume":"14","author":"Oe","year":"2015","journal-title":"Cardiovasc. Diabetol."},{"key":"2021113011014375700_B24","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/S0140-6736(14)61402-1","article-title":"Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy","volume":"385","author":"Gilbert","year":"2015","journal-title":"Lancet (London, England)"},{"key":"2021113011014375700_B25","doi-asserted-by":"crossref","first-page":"622","DOI":"10.5694\/j.1326-5377.2007.tb01078.x","article-title":"Management outcomes of patients with type 2 diabetes: targeting the 10-year absolute risk of coronary heart disease","volume":"186","author":"Yong","year":"2007","journal-title":"Med. J. Aust."},{"key":"2021113011014375700_B26","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"2021113011014375700_B27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.bbadis.2008.10.019","article-title":"Alterations of insulin signaling in type 2 diabetes: a review of the current evidence from humans","volume":"1792","author":"Fr\u00f6jd\u00f6","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"2021113011014375700_B28","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00125-005-1755-x","article-title":"Cardiac dysfunction induced by high-fat diet is associated with altered myocardial insulin signalling in rats","volume":"48","author":"Ouwens","year":"2005","journal-title":"Diabetologia"},{"key":"2021113011014375700_B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0120934","article-title":"The PKD inhibitor CID755673 enhances cardiac function in diabetic db\/db mice","volume":"10","author":"Venardos","year":"2015","journal-title":"PLoS ONE"},{"key":"2021113011014375700_B30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.pharmthera.2010.04.005","article-title":"Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies","volume":"128","author":"Bernardo","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"2021113011014375700_B31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1440-1681.2006.04342.x","article-title":"Cardiac hypertrophy, substrate utilization and metabolic remodelling: cause or effect?","volume":"33","author":"Ritchie","year":"2006","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"2021113011014375700_B32","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nrm1983","article-title":"Regulation of cardiac hypertrophy by intracellular signalling pathways","volume":"7","author":"Heineke","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2021113011014375700_B33","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.cardfail.2010.07.249","article-title":"Diabetic cardiomyopathy","volume":"16","author":"Murarka","year":"2010","journal-title":"J. Card. Fail."},{"key":"2021113011014375700_B34","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1161\/01.RES.82.11.1111","article-title":"Apoptosis: basic mechanisms and implications for cardiovascular disease","volume":"82","author":"Haunstetter","year":"1998","journal-title":"Circ. Res."},{"key":"2021113011014375700_B35","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1093\/emboj\/19.11.2537","article-title":"The conserved phosphoinositide 3-kinase pathway determines heart size in mice","volume":"19","author":"Shioi","year":"2000","journal-title":"EMBO J."},{"key":"2021113011014375700_B36","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.yjmcc.2004.07.008","article-title":"Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats","volume":"37","author":"Fiordaliso","year":"2004","journal-title":"J. Mol. Cell Cardiol."},{"key":"2021113011014375700_B37","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.lfs.2005.12.036","article-title":"Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes","volume":"79","author":"Fiordaliso","year":"2006","journal-title":"Life Sci."},{"key":"2021113011014375700_B38","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0092-8674(00)81883-8","article-title":"PI3K: downstream AKTion blocks apoptosis","volume":"88","author":"Franke","year":"1997","journal-title":"Cell"},{"key":"2021113011014375700_B39","doi-asserted-by":"crossref","first-page":"32841","DOI":"10.1074\/jbc.M513087200","article-title":"Akt2 regulates cardiac metabolism and cardiomyocyte survival","volume":"281","author":"DeBosch","year":"2006","journal-title":"J. Biol. Chem."},{"key":"2021113011014375700_B40","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1161\/CIRCHEARTFAILURE.114.001699","article-title":"Chronic administration of the nitroxyl donor 1-nitrosocyclo hexyl acetate limits left ventricular diastolic dysfunction in a mouse model of diabetes mellitus in vivo","volume":"8","author":"Cao","year":"2015","journal-title":"Circ. Heart Fail."},{"key":"2021113011014375700_B41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/461967","article-title":"Alteration of energy substrates and ROS production in diabetic cardiomyopathy","volume":"2013","author":"Lorenzo","year":"2013","journal-title":"Mediators Inflamm."},{"key":"2021113011014375700_B42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10741-010-9186-2","article-title":"NADPH oxidases and cardiac remodelling","volume":"16","author":"Nabeebaccus","year":"2011","journal-title":"Heart Fail. Rev."},{"key":"2021113011014375700_B43","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.2337\/db12-1391","article-title":"Hyperglycemia-induced protein kinase C \u03b22 activation induces diastolic cardiac dysfunction in diabetic rats by impairing caveolin-3 expression and Akt\/eNOS signaling","volume":"62","author":"Lei","year":"2013","journal-title":"Diabetes"},{"key":"2021113011014375700_B44","doi-asserted-by":"crossref","first-page":"827971","DOI":"10.1155\/2012\/827971","article-title":"Endoplasmic reticulum stress and diabetic cardiomyopathy","volume":"2012","author":"Xu","year":"2012","journal-title":"Exp. Diabetes Res."},{"key":"2021113011014375700_B45","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1097-2765(03)00105-9","article-title":"An integrated stress response regulates amino acid metabolism and resistance to oxidative stress","volume":"11","author":"Harding","year":"2003","journal-title":"Mol. Cell"},{"key":"2021113011014375700_B46","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1126\/science.1079474","article-title":"Role of EDEM in the release of misfolded glycoproteins from the calnexin cycle","volume":"299","author":"Molinari","year":"2003","journal-title":"Science (New York, N.Y.)"},{"key":"2021113011014375700_B47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2567.2006.02336.x","article-title":"Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia","volume":"118","author":"Khan","year":"2006","journal-title":"Immunology"},{"key":"2021113011014375700_B48","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nm1613","article-title":"Endothelial-to-mesenchymal transition contributes to cardiac fibrosis","volume":"13","author":"Zeisberg","year":"2007","journal-title":"Nat. Med."},{"key":"2021113011014375700_B49","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1745-7254.2005.00146.x","article-title":"Oxidative stress and stress signaling: menace of diabetic cardiomyopathy","volume":"26","author":"Wold","year":"2005","journal-title":"Acta Pharmacol. Sin."},{"key":"2021113011014375700_B50","doi-asserted-by":"crossref","first-page":"9491","DOI":"10.1128\/MCB.25.21.9491-9502.2005","article-title":"Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy","volume":"25","author":"Luo","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"2021113011014375700_B51","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.2337\/db10-0958","article-title":"Leptin therapy reverses hyperglycemia in mice with streptozotocin-induced diabetes, independent of hepatic leptin signaling","volume":"60","author":"Denroche","year":"2011","journal-title":"Diabetes"},{"key":"2021113011014375700_B52","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1128\/MCB.25.6.2498-2510.2005","article-title":"Insulin hypersensitivity and resistance to streptozotocin-induced diabetes in mice lacking PTEN in adipose tissue","volume":"25","author":"Kurlawalla-Martinez","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"2021113011014375700_B53","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet North Am. Ed."},{"key":"2021113011014375700_B54","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamacardio.2016.0008","article-title":"Intracoronary gene transfer of adenylyl cyclase 6 in patients with heart failure","volume":"1","author":"Hammond","year":"2016","journal-title":"JAMA Cardiol."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/131\/12\/1345\/448993\/cs-2017-0063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/131\/12\/1345\/448993\/cs-2017-0063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T11:56:36Z","timestamp":1638273396000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/131\/12\/1345\/72073\/Phosphoinositide-3-kinase-p110-gene-delivery"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,1]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,6,1]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20170063","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,1]]}}}